相似文献
1
Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series.
Ann Rheum Dis. 2022 Feb;81(2):291-293. doi: 10.1136/annrheumdis-2021-221206. Epub 2021 Sep 7.
2
Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
Ann Rheum Dis. 2021 Oct;80(10):e162. doi: 10.1136/annrheumdis-2021-220756. Epub 2021 Jul 16.
3
Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series.
Ann Rheum Dis. 2022 Feb;81(2):293-295. doi: 10.1136/annrheumdis-2021-221252. Epub 2021 Sep 23.
4
Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
Immunol Res. 2021 Dec;69(6):576-583. doi: 10.1007/s12026-021-09226-z. Epub 2021 Aug 21.
5
Humoral Immune Response to SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases.
Arch Med Res. 2025 Apr;56(3):103141. doi: 10.1016/j.arcmed.2024.103141. Epub 2025 Jan 6.
6
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.
Microbiol Spectr. 2024 Oct 3;12(10):e0060524. doi: 10.1128/spectrum.00605-24. Epub 2024 Aug 20.
7
Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion.
Arthritis Rheumatol. 2022 Jan;74(1):33-37. doi: 10.1002/art.41914. Epub 2021 Nov 23.
8
Humoral immune response as an indicator for protection against Covid-19 after anti-SARS-COV2-booster vaccination in hematological and oncological patients.
Int J Cancer. 2024 Dec 15;155(12):2141-2148. doi: 10.1002/ijc.35162. Epub 2024 Sep 2.
9
Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.
Front Immunol. 2025 Mar 6;16:1538453. doi: 10.3389/fimmu.2025.1538453. eCollection 2025.
10
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
Ann Rheum Dis. 2021 Oct;80(10):1322-1329. doi: 10.1136/annrheumdis-2021-220626. Epub 2021 Aug 6.
引用本文的文献
1
Impaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD Patients.
Cells. 2025 Jul 26;14(15):1156. doi: 10.3390/cells14151156.
2
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase.
J Transl Autoimmun. 2023 Oct 9;7:100212. doi: 10.1016/j.jtauto.2023.100212. eCollection 2023 Dec.
3
SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort.
Front Immunol. 2023 Jul 20;14:1185278. doi: 10.3389/fimmu.2023.1185278. eCollection 2023.
4
Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019.
Rheum Dis Clin North Am. 2023 Aug;49(3):695-711. doi: 10.1016/j.rdc.2023.03.007. Epub 2023 Mar 14.
5
Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases.
J Immunol. 2023 Aug 1;211(3):351-364. doi: 10.4049/jimmunol.2300190.
6
Vaccine hesitancy in patients with COVID-19 who have back pain.
Osong Public Health Res Perspect. 2023 Apr;14(2):100-109. doi: 10.24171/j.phrp.2023.0003. Epub 2023 Mar 24.
7
Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study.
Vaccines (Basel). 2023 Apr 10;11(4):819. doi: 10.3390/vaccines11040819.
8
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases.
RMD Open. 2023 Apr;9(2). doi: 10.1136/rmdopen-2023-002998.
9
The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What.
Vaccines (Basel). 2022 Nov 14;10(11):1924. doi: 10.3390/vaccines10111924.
10
Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients.
Front Immunol. 2022 Oct 31;13:1033804. doi: 10.3389/fimmu.2022.1033804. eCollection 2022.
本文引用的文献
1
BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.
Clin Microbiol Infect. 2021 Nov;27(11):1652-1657. doi: 10.1016/j.cmi.2021.06.036. Epub 2021 Jul 7.
2
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
3
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
Ann Intern Med. 2021 Sep;174(9):1330-1332. doi: 10.7326/L21-0282. Epub 2021 Jun 15.
4
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Oct;80(10):1351-1352. doi: 10.1136/annrheumdis-2021-220656. Epub 2021 May 24.
5
Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
Ann Intern Med. 2021 Sep;174(9):1332-1334. doi: 10.7326/M21-1451. Epub 2021 May 25.
Zotero 插件